Valuation

Leader in evidence-based evaluations for life sciences companies

Collaboration with BioScience Valuation GmbH

Togetherwith BioScience Valuation GmbH, a provider of evidence-based valuations and market models, FCF Life Sciences focuses on the development of integrated financial models as well as budgets.

Service Portfolio

for Pharmaceutical companies:

  • Determination of project value and support of portfolio management decisions
  • Assessment of in-licensing  candidates and potential M&A transactions
  • Drug’s sales forecast
  • Increase R&D productivity
  • Optimization of resource and capacity planning

for Biotech / MedTech companies:

  • Identification of licensing partners, optimizing term sheets and leveraging negotiations
  • Preparation of funding rounds to attract investors

for Healthcare companies and organizations:

  • Assessment of economic impact of policies
  • Facilitation of healthcare policy decisions

for Investors:

  • Facilitation of investment decisions
  • Support of due diligence

Notable Past Clients

  • AiCuris GmbH & Co. KG
  • Alligator Bioscience AB
  • Bayer HealthCare
  • Boehringer Ingelheim
  • Cell Medica
  • Daiichi Sankyo Europe
  • Ferring Pharmaceuticals
  • Fresenius Biotech GmbH
  • Grünenthal GmbH
  • Heidelberg Pharma
  • Spirogene Pty Ltd
  • Hoffman-La Roche Ltd.
  • Janus Developments SL
  • Jerini AG
  • MediGene AG
  • Merck KGaA
  • MorphoSys AG
  • Novalead Pharma Pvt. Ltd.
  • Oryzon SA
  • Rentschler Biotechnologie
  • Schwarz Pharma AG
  • Solvay Pharmaceuticals
  • The Genetics Company
  • UCB Pharma SA

PROJECT INSIGHTS

If you are interested in discussing valuation projects, please contact us:

[a-zA-Z0-9_.-]
[a-zA-Z0-9_.-]
[a-zA-Z0-9]
[a-zA-Z0-9]